Urokinase is mainly used in thrombolytic therapy for thromboembolic diseases. Patients with acute generalized pulmonary embolism, coronary artery embolization and myocardial infarction within 6 to 12 hours of chest pain, acute cerebral vascular embolization with symptoms less than 3 to 6 hours, retinal artery embolization and other peripheral arterial embolization with severe ilio-femoral vein thrombosis were included. It is also used to prevent thrombosis after artificial heart valve operation, maintain the vascular intubation and unobstructed thoracic and pericardial drainage tube, etc. The effect of thrombolysis needs to be maintained by subsequent heparin anticoagulation.

　　This product is contraindicated in patients with the following conditions: acute visceral hemorrhage, acute intracranial hemorrhage, old cerebral infarction, intracranial or spinal surgery performed within the last two months, intracranial tumor, arteriovenous malformation or aneurysm, bleeding diathesis, and severe uncontrolled hypertension. Relative contraindication includes prolonged cardiopulmonary resuscitation, severe hypertension, trauma within nearly 4 weeks, surgery or tissue puncture within 3 weeks, pregnancy, 10 days after delivery, active ulcer disease.

　　Above is urokinase related introduction, if needs to learn more please continue to follow kang Yuan website.